A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Cold Agglutinin Disease (CAD).

[Translated article] Good humanisation practices in the healthcare of patients with rare diseases in Pharmacy Services

Company Albir MJ, Andrés JLP, Solsona MDE

Article. 10.1016/j.farma.2023.10.004. 2024

A multicentre ambispective observational study into the incidence and clinical management of aplastic anaemia in Spain (IMAS study)

Vallejo C; (...); Codesido ML

Article. 10.1007/s00277-023-05602-x. 2024

• 1

  

A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.

Zozaya, Neboa; (...); Verde, Luis

Article. 10.1017/S0266462322000459. 2022

• 
• 
• 3

  

ADAMTS13 RECOVERY IN ACUTE THROMBOTIC THROMBOCYTOPENIC PURPURA AFTER CAPLACIZUMAB THERAPY. THE SPANISH REGISTRY.

Mingot-Castellano, Maria Eva; (...); Pascual Izquierdo, Cristina

Article. 10.1182/blood.2023022725. 2024

• 
• 9

  

Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).

Pereyra-Rodríguez JJ; (...); Ortiz de Frutos FJ

Letter. 10.1111/jdv.19432. 2023

• 
• 
• 1

  

Caplacizumab Treatment in Elderly Patients with iTTP: Updated Experience from the Spanish TTP Registry

Gomez Segui, Ines; (...); De La Rubia, Javier

Meeting Abstract. 10.1182/blood-2023-180970. 2023

• 
• 1

  

CMV REACTIVATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FROM HLA-MATCHED AND HAPLOIDENTICAL DONORS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE.

Chorão P; (...); Sanz J

Article. 10.1016/j.jtct.2024.01.082. 2024

• 
• 6

  

Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano JB; (...); Soto-Ortega I

Article. 10.1016/j.farma.2023.01.003. 2023

Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada

Article. 10.1016/j.farma.2023.04.002. 2023

Correction: Vitamin C and folate status in hereditary fructose intolerance.

Cano A; (...); de Las Heras J

Correction. 10.1038/s41430-023-01334-3. 2023

• 
• 1

  

Cytokine response as a biomarker for early diagnosis and outcome prediction of stem cell transplant recipients and acute leukemia patients with invasive aspergillosis.

Puerta-Alcalde, Pedro; (...); Garcia-Vidal, Carolina

Article. 10.1093/mmy/myac038. 2022

• 2

  

Chronic liver disease-associated severe thrombocytopenia in Spain: Results from a retrospective study using machine learning and natural language processing.

Calleja-Panero, Jose Luis; (...); Gonzalez Calvo, Jose

Article. 10.1016/j.gastrohep.2023.05.010. 2023

• 
• 
• 1

  

Design and Validation of a Custom Next-Generation Sequencing Panel in Pediatric Acute Lymphoblastic Leukemia.

Gil, Jose Vicente; (...); Barragan, Eva

Article. 10.3390/ijms24054440. 2023

• 
• 
• 4

  

Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.

Abad, Maria Reyes; (...); Gil, Alicia

Article. 10.33393/grhta.2024.3041. 2024

• 
• 2

  

Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis

Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther

Article. 10.1002/jvc2.275. 2024

Effect of autologous umbilical cord blood transfusion in the development of retinopathy of prematurity: randomized clinical trial - study protocol.

Torrejon-Rodriguez L; (...); Aguar Carrascosa M

Article. 10.3389/fped.2023.1269797. 2023

• 
• 
• 4

  

Effect of Caplacizumab in the Recovery of ADAMTS13 Level in Patients with Autoimmune Thrombotic Thrombocytopenic Purpura. Analysis from the Spanish Registry (REPTT)

Eva Mingot, Maria; (...); Del Rio Garma, Julio

Meeting Abstract. 10.1182/blood-2023-182876. 2023

• 2

  

Enhancing Cytogenetic Diagnostics: Incorporating Optical Genome Mapping in the Laboratory Routine

Diaz-Gonzalez, Alvaro; (...); Such, Esperanza

Meeting Abstract. 10.1182/blood-2023-180691. 2023

• 
• 1

  

Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Ayyappan, Sabarish; (...); Prince, H. Miles

Meeting Abstract. 10.1182/blood-2023-179818. 2023

• 
• 
• 31

  

Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study.

de la Rubia J; (...); Bonanad, Santiago

Article. 10.1016/j.jgo.2022.10.016. 2022

• 
• 
• 13

  

Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study

Iskierka-Jazdzewska, Elzbieta; (...); Ivanescu, Cristina

Meeting Abstract. 10.1182/blood-2023-180743. 2023

• 
• 
• 3

  

How can artificial intelligence optimize value-based contracting?

Poveda, Jose Luis; (...); Medrano, Ignacio H.

Letter. 10.1186/s40545-022-00475-3. 2022

• 
• 
• 3

  

IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic Patients.

Vallejo, Carlos; (...); Peman, Javier

Article. 10.3390/jof9060628. 2023

• 
• 
• 2

  

Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease

Lakhwani, Sunil; (...); Hernandez, Miguel-Teodoro

Meeting Abstract. 10.1182/blood-2022-166826. 2022

IMPACT OF POSTTRANSPLANT CYCLOPHOSPHAMIDE ON TRANSFUSION REQUIREMENTS IN HLA MATCHED SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION.

Marco-Ayala, Javier; (...); Solves, Pilar

Article. 10.1016/j.jtct.2023.01.009. 2023

• 
• 11

  

Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma.

Martinez, Carmen; (...); Garcia-Sanz, Ramon

Article. 10.1007/s00277-022-05011-6. 2022

• 
• 5

  

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.

Rosinol, Laura; (...); Blade, Joan

Article. 10.1182/blood.2022019531. 2023

• 
• 26

  

Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO.

Martin Garcia-Sancho, A.; (...); Caballero, D.

Article. 10.1111/bjh.18989. 2023

Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.

Vázquez Polo A; (...); Vázquez Costa JF

Article. 10.20960/nh.03946. 2022

National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies

Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis

Meeting Abstract. 10.1182/blood-2022-169938. 2022

Novel Agents May be Preferable to Standard Chemotherapy in Second-Line for Early Relapsing Follicular Lymphoma (FL) Patients

Serna, Angel; (...); Abrisqueta Costa, Pau

Meeting Abstract. 10.1182/blood-2023-186019. 2023

Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus

Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis

Article. 10.1097/MD.0000000000032208. 2022

• 
• 
• 1

  

Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Kim, Won-Seog; (...); Walewski, Jan

Meeting Abstract. 10.1182/blood-2022-158406. 2022

• 
• 
• 28

  

ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.

Poveda JL; (...); Badia X

Article. 10.1186/s13023-022-02610-4. 2023

• 
• 
• 1

  

Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial

Cabrero M; (...); Caballero D

Article. 10.1038/s41409-023-02171-5. 2024

• 
• 
• 1

  

Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes

Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor

Review. 10.3390/biology12091159. 2023

• 
• 
• 4

  

Paradoxical Findings in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors: Suboptimal Disease Control Perceived As Satisfactory

Gaya, Anna; (...); Vallejo, Carlos

Meeting Abstract. 10.1182/blood-2023-185939. 2023

Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services

Company Albir MJ, Poveda Andrés JL, Edo Solsona MD

Article. 10.1016/j.farma.2023.06.0131130. 2024

Primary and secondary immune thrombocytopenia (ITP): Time for a rethink.

Gonzalez-Lopez, Tomas Jose; (...); Fernandez-Fuertes, Fernando

Article. 10.1016/j.blre.2023.101112. 2023

• 
• 11

  

Prognostic Factors and Treatment Strategy in Patients with Hodgkin Lymphoma and HIV Infection Treated with ABVD and CART: A Retrospective Study from Spanish Group Geltamo

Huguet, Maria; (...); Navarro, Jose-Tomas

Meeting Abstract. 10.1182/blood-2023-189756. 2023

• 
• 1

  

Real-world effectiveness of caplacizumab vs standard of care in immune thrombotic thrombocytopenic purpura.

Pascual Izquierdo, Maria Cristina; (...); Del Rio-Garma, Julio

Article. 10.1182/bloodadvances.2022008028. 2022

• 
• 
• 40

  

Real-World Experience in Extracorporeal photopheresisfor adults with graft-versus-host disease.

Asensi Cantó P; (...); Gómez-Seguí I

Article. 10.1016/j.jtct.2023.09.001. 2023

• 
• 
• 5

  

Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI).

Mingot-Castellano, Maria Eva; (...); Pascual-Izquierdo, Cristina

Article. 10.3390/jcm12206422. 2023

• 
• 
• 14

  

Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease

Lakhwani, Sunil; (...); Hernandez, Miguel-Teodoro

Meeting Abstract. 10.1182/blood-2022-167247. 2022

• 
• 2

  

Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.

Lakhwani S; (...); Hernández MT

Article. 10.3324/haematol.2023.284154. 2024

• 
• 
• 3

  

Reduced incidence of neurologic complications after allogeneic hematopoietic stem cell transplantation with calcineurin-free graft-versus-host disease prophylaxis.

Balaguer-Rosello, Aitana; (...); Sanz, Jaime

Article. 10.1016/j.jtct.2023.07.008. 2023

Should we consider caplacizumab as routine treatment for acute thrombotic thrombocytopenic purpura? An expert perspective on the pros and cons.

Seguí IG; (...); de la Rubia J

Article. 10.1080/17474086.2024.2318347. 2024

• 2

  

Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease

Lakhwani, Sunil; (...); Teodoro Hernandez Garcia, Miguel

Meeting Abstract. 10.1182/blood-2023-179452. 2023

T-cell Depleted Peripheral Blood versus Unmanipulated Bone Marrow in Matched Sibling Transplantation for Aplastic Anemia.

Chorao, Pedro; (...); Sanz, Jaime

Article. 10.1016/j.jtct.2023.01.016. 2023

• 
• 
• 2

  

The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity

Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar

Article. 10.1007/s00431-022-04628-z. 2022

• 
• 1

  

Transfusion Burden in Allogeneic Hematopoietic Stem Cell Transplantation over Time: Experience from a Single Institution.

Solves, Pilar; (...); Sanz, Jaime

Article. 10.3390/jcm12103467. 2023

• 
• 
• 1

  

VALUE CRITERIA FOR OUTCOMES BASED MANAGED ENTRY AGREEMENT OF CAR-T IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) THROUGH MCDA

Poveda, J. L.; (...); Lizan, L.

Meeting Abstract. 2023